FierceBiotech6h
After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
The Pharma Letter7h
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...
Relmada acquires new Tourette syndrome treatment asset
CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...
Relmada Therapeutics acquires Sepranolone from Asarina Pharma
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement ...